Last updated: October 8, 2026
PhRMA sued in federal court on October 7 to block Medicare’s GLOBE most favored nation pricing model before its January start, while Caribou Biosciences halted both allogeneic CAR T programs for lack of funding and Cerevance’s solengepras met its Phase 3 primary endpoint in Parkinson’s disease.
This page covers the business day of Wednesday, October 7, 2026, across policy, clinical results, intellectual property, and capital markets.
Why did PhRMA sue to block the GLOBE model?
The Pharmaceutical Research and Manufacturers of America filed suit on October 7 in the US District Court for the District of Columbia, asking the court to declare the GLOBE model unlawful and vacate the rule. The complaint argues CMS is using demonstration authority to impose nationwide price setting Congress never authorized.
The defendants named in coverage of the filing are the Department of Health and Human Services, Secretary Robert F. Kennedy Jr., CMS, Administrator Mehmet Oz, and CMS Innovation Center director Abe Sutton, per Reuters. According to Pharmaceutical Commerce’s account of the complaint, PhRMA makes three core arguments: that mandatory manufacturer rebates predetermine the model’s outcome, so the rule does not test anything in the way the Innovation Center statute requires; that GLOBE overrides Medicare’s statutory rebate structure and expands civil monetary penalties beyond CMS’s authority; and that the policy raises separation of powers problems. PhRMA chief executive Stephen J. Ubl said in the group’s statement that “GLOBE is unlawful and clearly exceeds CMS’ authority” and that “CMS cannot rewrite the law and bypass Congress to impose foreign price controls.”
The agency has anticipated the argument. In the final rule’s own text, quoted by Reuters, CMS wrote that it “is acting within a detailed, purpose specific statutory framework that Congress designed precisely.” HHS did not immediately comment on the suit. PhRMA has won this fight once before: its challenge helped sink the first most favored nation interim final rule in 2020, though that ruling turned on the government skipping notice and comment, a procedural defect the GLOBE rulemaking does not share.
| GLOBE model fact | Detail |
|---|---|
| Finalized | September 30, 2026 |
| Runs | January 1, 2027 through March 31, 2032, with reconciliation through March 31, 2034 |
| Mechanism | Alternative rebate formula benchmarking certain separately payable Part B drugs against international prices |
| Geography | Randomly selected areas covering roughly 25% of Original Medicare enrollment |
| Exclusions | Orphan only drugs, plasma derived products, certain cell and gene therapies, biosimilars and their reference products once a biosimilar launches |
| Relief sought | Declaration that the rule is unlawful, and vacatur |
What did the lawsuit’s timing reveal about the model’s shrinking scope?
The suit landed a week after CMS finalized a rule that is already a fraction of its proposed self. Per Reuters, HHS now estimates GLOBE will cut Medicare Part B spending by about $440 million over its run, down from roughly $11.9 billion projected in the proposed rule.
The shrinkage has one main cause: CMS will waive the rebate requirement for manufacturers that have signed separate pricing agreements with the White House. With more than two dozen drugmakers having signed such deals, including Pfizer, Eli Lilly, and Novo Nordisk, Reuters reports the model may end up applying to as few as four manufacturers. That arithmetic cuts both ways in court and in Washington. A model that touches almost nobody is harder to defend as a meaningful test, which is PhRMA’s point. It is also harder to attack as an industry wide taking, which will be the government’s. The suit keeps pressure on the one lever the pledge system depends on: the credibility of the penalty waiting for companies that do not sign.
Why is Caribou Biosciences shutting down its CAR T programs?
Caribou Biosciences said it will discontinue both of its clinical stage allogeneic CAR T programs, substantially reduce its workforce, and evaluate strategic alternatives including a merger, acquisition, or asset sales, because it could not raise capital for allogeneic CAR T development. The announcement crossed late on October 6 and the stock lost nearly half its remaining value on Wednesday.
The programs being halted are vispa-cel, an allogeneic anti CD19 CAR T for relapsed or refractory B cell non Hodgkin lymphoma, and CB-011, an allogeneic anti BCMA CAR T for relapsed or refractory multiple myeloma. What makes the decision notable is where vispa-cel stood: the company described it as pivotal trial ready, with FDA alignment on a Phase 3 design, and coverage of the release notes the program held regenerative medicine advanced therapy and Fast Track designations. Chief executive Rachel Haurwitz framed the decision as a verdict on the financing environment for allogeneic cell therapy rather than on the data, per AllSci’s account of the release. The board approved the restructuring on October 2. Caribou reported $113.8 million in cash, cash equivalents, and marketable securities as of June 30, 2026, and Wedbush Securities is acting as exclusive financial adviser for the strategic review. Workforce reductions are expected to be largely complete in the fourth quarter.
The industry significance is blunt. A genome edited, off the shelf CAR T platform founded on Jennifer Doudna’s science, with a Phase 3 ready lead asset, concluded that the capital to run that trial does not exist at an acceptable price. One day earlier, ArriVent showed what happens when a company does fund its own registrational binary and misses. Caribou is the other end of the same curve: the companies that cannot get to the starting line at all.
What did Cerevance’s solengepras show in the Phase 3 ARISE trial?
Solengepras, a once daily oral, non dopaminergic GPR6 inhibitor taken as an add on to levodopa, reduced daily OFF time by 0.61 hours more than placebo at Week 12 (p=0.0350) in the 341 patient ARISE trial, meeting the primary endpoint at the 150 mg dose with placebo like tolerability.
ARISE randomized patients with Parkinson’s disease experiencing motor fluctuations 1:1:1 to solengepras 150 mg (n=113), 75 mg (n=114), or placebo (n=114) on top of levodopa and other medications for 12 weeks. Baseline OFF time averaged 5.65 hours per day and 91% of participants completed the trial. The company’s release reports results for the 150 mg arm; figures for the 75 mg arm were not reported.
| ARISE endpoint (150 mg vs placebo, Week 12) | Result | p value |
|---|---|---|
| Daily OFF time (primary) | Reduction of 1.56 hours vs 0.95 hours; placebo adjusted 0.61 hours | 0.0350 |
| ON time without troublesome dyskinesia | Placebo adjusted gain of 0.60 hours | 0.0468 |
| MDS-UPDRS Part II | Placebo adjusted improvement of 1.91 points | 0.0008 |
| Epworth Sleepiness Scale | Placebo adjusted improvement of 0.98 points | 0.009 (nominal) |
| PDQ-39 quality of life | Placebo adjusted improvement of 2.87 points | 0.012 (nominal) |
Safety was clean by the standards of the add on class. Discontinuations due to adverse events were 3.5% in all three arms including placebo, no serious adverse events occurred on 150 mg, and dyskinesia was reported in 4.4% of the 150 mg arm versus 1.8% on placebo. Solengepras targets the striatal indirect pathway without acting directly on dopamine receptors, which is the mechanistic basis for the company’s first in class claim. The result rehabilitates a program that missed in a mid stage trial in April 2025 on a physician administered exam endpoint, per Fierce Biotech. Cerevance, a privately held Boston company, says it will meet with the FDA to discuss a potential path to a New Drug Application; it gave no submission timing.
What did the Dutch court order against Keytruda SC do?
A patent court in The Hague found Merck infringed a Halozyme MDASE patent and ordered it to stop producing and selling subcutaneous Keytruda in eight European countries: Belgium, Denmark, France, Ireland, Italy, Sweden, Switzerland, and the Netherlands, per Reuters.
The ruling extends a dispute that already produced a German preliminary injunction against Keytruda SC last year, and sits alongside a US case in which Halozyme alleges the subcutaneous formulation infringes 15 of its patents. Halozyme chief legal officer Mark Snyder said the company was pleased the court recognized the validity and infringement of the MDASE patent; Merck did not immediately comment. The commercial stakes are structural rather than immediate. Merck is counting on the subcutaneous format to defend the Keytruda franchise as intravenous exclusivity erodes late this decade, and the market’s reaction suggested investors see the European setback as manageable: Merck closed at $142.79, up 0.6%, and Halozyme at $110.79, up 1.0%, both our arithmetic from settled closes.
How much did Ultragenyx get for its priority review voucher?
Ultragenyx agreed to sell a rare pediatric disease priority review voucher for $210 million in cash, per an 8-K filed October 7. The buyer was not named. The FDA awarded the voucher on August 19, 2026 with the approval of GENGLYCOS, the company’s gene therapy for glycogen storage disease type Ia.
Two details in the filing matter for anyone modeling voucher economics. First, the sale is subject to Hart Scott Rodino clearance, a reminder that even voucher transfers now route through antitrust review. Second, Ultragenyx owes the National Institutes of Health 20% of gross proceeds under a 2018 patent license tied to the underlying program, so the headline number overstates what the company keeps. Endpoints News notes Ultragenyx has another voucher it intends to monetize. At $210 million, the regulatory currency continues to clear at prices well above where vouchers traded in the middle of the decade, a point worth holding next to Caribou’s news: the same market that will pay nine figures for a de risked piece of regulatory paper would not fund a pivotal ready cell therapy.
What else happened in life sciences on October 7, 2026?
Several running stories advanced. BD’s October 6 press release describing its US government partnership is now live on the company newsroom, confirming the figures that circulated as statements a day earlier: $19 billion of US investment over several years including $3 billion for manufacturing, capacity for roughly 5 billion additional essential medical consumables per year, a path to about 80% of BD’s US supplied essential consumables being made domestically, and a commitment to make 100% of needles used in America domestically with American made steel, in exchange for relief from future Section 232 tariffs conditional on final scope and milestones.
Medtronic set the final exchange ratio for its MiniMed split off at 4.5939 MiniMed shares per Medtronic share accepted, with the exchange offer expiring at midnight New York time at the end of October 9; the company said that if the offer is oversubscribed it currently intends to exchange its remaining interest of 27,452,053 additional shares without extending the offer. TCGX launched its $600 million Asia Life Sciences Fund I, per the firm’s announcement reported by Fierce Biotech, with offices opening in Shanghai and Hong Kong, a signal that US crossover capital is formalizing its China exposure rather than retreating from it. And ARPA-H’s Surpass program, announced September 30 and detailed in trade coverage this week, will fund simulation augmented adaptive trial infrastructure alongside companion efforts in site activation, consent architecture, and patient navigation.
Which stocks moved on the day’s news?
Settled closes for Wednesday, October 7, 2026, with percentage changes computed from the prior session’s settled closes (our arithmetic).
| Company | Ticker | Oct 7 close | Change | Context |
|---|---|---|---|---|
| Caribou Biosciences | CRBU | $0.62 | −45.6% | First session after the wind down announcement crossed late October 6 |
| Ultragenyx | RARE | $14.89 | +3.0% | $210 million voucher sale disclosed in an 8-K |
| Halozyme | HALO | $110.79 | +1.0% | Dutch court order against Keytruda SC in eight countries; muted follow through |
| Merck | MRK | $142.79 | +0.6% | Market treated the European subcutaneous setback as manageable |
| Spyre Therapeutics | SYRE | $80.85 | +0.9% | Second session after the $350 million offering; still about 4.9% below the $85.00 offer price, our arithmetic |
Frequently asked questions
What is the GLOBE model?
GLOBE is a mandatory CMS Innovation Center model, finalized September 30, 2026, that tests an alternative rebate formula benchmarking certain separately payable Medicare Part B drugs against international prices in randomly selected areas covering about 25% of Original Medicare, from January 1, 2027 through March 31, 2032.
Who did PhRMA sue over the GLOBE model?
PhRMA filed in the US District Court for the District of Columbia; Reuters reports the defendants include HHS, Secretary Robert F. Kennedy Jr., CMS, Administrator Mehmet Oz, and CMS Innovation Center director Abe Sutton.
What are PhRMA’s main legal arguments against GLOBE?
Per accounts of the complaint, PhRMA argues the mandatory rebates predetermine outcomes rather than testing a model, that GLOBE overrides Medicare’s statutory rebate structure, that civil monetary penalties are expanded beyond CMS’s authority, and that the rule raises separation of powers problems.
Could the GLOBE model really apply to only a few drugmakers?
Reuters reports CMS will waive the model’s requirements for manufacturers with separate White House pricing agreements, and with more than two dozen companies signed, the model may apply to as few as four drugmakers.
Has PhRMA beaten a most favored nation rule before?
Yes. Legal challenges including PhRMA’s helped block the 2020 most favored nation interim final rule, which courts faulted for skipping notice and comment. The GLOBE rule went through full rulemaking, so that specific defect does not carry over.
Why is Caribou Biosciences winding down?
Caribou said it could not raise capital for allogeneic CAR T development. It is discontinuing vispa-cel and CB-011, substantially reducing its workforce by the fourth quarter of 2026, and evaluating strategic alternatives with Wedbush Securities as adviser.
Was vispa-cel failing in the clinic?
The company did not attribute the decision to clinical results. Vispa-cel was described as pivotal trial ready with FDA alignment on a Phase 3 design, and coverage notes the program held RMAT and Fast Track designations.
How much cash did Caribou have?
Caribou reported $113.8 million in cash, cash equivalents, and marketable securities as of June 30, 2026, per its release.
What is solengepras and how does it work?
Solengepras (CVN424) is a once daily oral drug that inhibits the GPR6 receptor on the striatal indirect pathway. It is non dopaminergic, meaning it does not act directly on dopamine receptors or dopamine levels, which Cerevance argues could avoid typical dopaminergic side effects.
What did the ARISE trial show for solengepras?
At 150 mg, solengepras reduced daily OFF time by 0.61 hours versus placebo at Week 12 (p=0.0350), increased ON time without troublesome dyskinesia by 0.60 hours (p=0.0468), and improved MDS-UPDRS Part II by 1.91 points (p=0.0008), with discontinuation rates matching placebo.
Will Cerevance file for FDA approval of solengepras?
Cerevance says it plans to meet with the FDA to discuss a potential path to a New Drug Application. It has not given a submission timeline.
Which countries are covered by the Keytruda SC court order?
Belgium, Denmark, France, Ireland, Italy, Sweden, Switzerland, and the Netherlands, per Reuters. A separate German preliminary injunction was issued last year.
Does the Dutch ruling affect intravenous Keytruda?
No. The order covers the subcutaneous formulation, which Merck is positioning to defend the franchise as intravenous exclusivity erodes later this decade.
How much is a priority review voucher worth in 2026?
Ultragenyx’s agreement to sell its rare pediatric disease voucher for $210 million in cash is the latest print. Ultragenyx will owe the NIH 20% of gross proceeds under a 2018 patent license, and the sale needs Hart Scott Rodino clearance.
When does Medtronic’s MiniMed exchange offer expire?
At midnight New York City time at the end of October 9, 2026, with a final exchange ratio of 4.5939 MiniMed shares per Medtronic share accepted.
Sources
Primary sources: Cerevance press release via GlobeNewswire (October 7, 2026); Ultragenyx Form 8-K (SEC, filed October 7, 2026); BD press release, news.bd.com (October 6, 2026); Caribou Biosciences press release via GlobeNewswire (October 6, 2026), accessed via RTTNews and AllSci carries; Medtronic press release (October 7, 2026) via StockTitan; CMS GLOBE final rule (September 30, 2026) as quoted by Reuters.
Trade and wire coverage (October 7, 2026): Reuters (PhRMA suit; Halozyme order) via KFGO; Pharmaceutical Commerce (complaint detail); Endpoints News (PhRMA suit; Ultragenyx vouchers); Fierce Biotech (Cerevance context; Caribou; TCGX; ARPA-H Surpass); BioSpace (Caribou; Cerevance); Bloomberg Law and STAT (filing confirmations). Settled closes from exchange close data; percentage changes are our arithmetic.
Related coverage
- ArriVent’s firmonertinib missed its Phase 3 endpoint in first line exon 20 lung cancer as Vaxcyte raised $1 billion and Stryker named Spencer Stiles CEO (October 7, 2026)
- Vaxcyte’s VAX-31 met all primary endpoints in its pivotal adult Phase 3 as Shionogi paid $2 billion for IntraBio and GE HealthCare bought Sofie for $945 million (October 6, 2026)
- Lilly’s EloraTZP cut weight 23.3% in Phase 2 diabetes and obesity data as Foundayo passed its cardiovascular safety test and CMS finalized the GLOBE rule (October 1, 2026)
